Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
| Status: | Archived |
|---|---|
| Conditions: | Skin Cancer, Cancer, Cancer, Kidney Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2009 |
| End Date: | September 2012 |
Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated
Killer cells (LAK). This study will determine if these killer cells are able to kill
certain standard cell-lines in the laboratory.
Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to
measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The
LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic
dehydrogenase release from lysed cells.
We found this trial at
1
site
Click here to add this to my saved trials
